| Irisin/FNDC5-An updated review. K Panati, Y Suneetha, VR Narala European Review for Medical & Pharmacological Sciences 20 (4), 2016 | 144 | 2016 |
| Curcumin nanotechnologies and its anticancer activity PA Subramani, K Panati, VR Narala Nutrition and cancer 69 (3), 381-393, 2017 | 59 | 2017 |
| Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ VR Narala, MR Smith, RK Adapala, R Ranga, K Panati, BB Moore, T Leff, ... Gene therapy & molecular biology 13 (1), 20, 2009 | 59 | 2009 |
| Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the TH2 cytokines FB Shaik, K Panati, VR Narasimha, VR Narala Biochemical and Biophysical Research Communications 463 (4), 600-605, 2015 | 43 | 2015 |
| The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation VR Narala, PA Subramani, VR Narasimha, FB Shaik, K Panati international immunopharmacology 23 (1), 283-287, 2014 | 39 | 2014 |
| Ovarian cancer biology and immunotherapy TS Latha, K Panati, DSK Gowd, MC Reddy, D Lomada International reviews of immunology 33 (5), 428-440, 2014 | 37 | 2014 |
| Association of single nucleotide polymorphisms (SNPs) of PADI4 gene with rheumatoid arthritis (RA) in Indian population K Panati, S Pal, R KV, VD Reddy Genes & genetic systems 87 (3), 191-196, 2012 | 36 | 2012 |
| Code inside the codon: The role of synonymous mutations in regulating splicing machinery and its impact on disease A Sarkar, K Panati, VR Narala Mutation Research/Reviews in Mutation Research 790, 108444, 2022 | 31 | 2022 |
| Nanostructures for curcumin delivery: possibilities and challenges PA Subramani, K Panati, VR Lebaka, DD Reddy, VR Narala Nano-and Microscale Drug Delivery Systems, 393-418, 2017 | 29 | 2017 |
| COVID-19 outbreak: an update on therapeutic options K Panati, VR Narala SN Comprehensive Clinical Medicine 2 (4), 379-380, 2020 | 23 | 2020 |
| Expression, purification and biological characterisation of recombinant human irisin (12.5 kDa) K Panati, VR Narala, VR Narasimha, M Derangula, VRRA Tatireddigari, ... Journal of Genetic Engineering and Biotechnology 16 (2), 459-466, 2018 | 22 | 2018 |
| Nano‐and Micro‐scale Drug Delivery Systems PA Subramani, K Panati, VR Lebaka, DD Reddy, VR Narala, ... Elsevier, 2017 | 21 | 2017 |
| Anticancer activities of biogenic silver nanoparticles targeting apoptosis and inflammatory pathways in colon cancer cells VR Narasimha, TS Latha, R Pallu, K Panati, VR Narala Journal of Cluster Science 33 (5), 2215-2231, 2022 | 20 | 2022 |
| The nitrated fatty acid, 10-nitrooleate inhibits the neutrophil chemotaxis via peroxisome proliferator-activated receptor gamma in CLP-induced sepsis in mice K Panati, PA Subramani, MM Reddy, M Derangula, VRRA Tatireddigari, ... International Immunopharmacology 72, 159-165, 2019 | 15 | 2019 |
| Biochanin A ameliorates ovalbumin-induced airway inflammation through peroxisome proliferator-activated receptor-gamma in a mouse model M Derangula, K Panati, VR Narala Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2021 | 13 | 2021 |
| Electrophilic nitrated fatty acids are potential therapeutic candidates for inflammatory and fibrotic lung diseases K Panati, LV Thimmana, VR Narala Nitric Oxide 102, 28-38, 2020 | 13 | 2020 |
| Recombinant approach for the production of HIV fusion inhibitor Enfuvirtide using Escherichia coli RR Kosana, C Bajji, RM Kanumuri, K Panati, LN Mangamoori, ... Protein Expression and Purification 95, 136-142, 2014 | 8 | 2014 |
| Nitrated fatty acid, 10-nitrooleate protects against hyperoxia-induced acute lung injury in mice VR Narala, LV Thimmana, K Panati, N Kolliputi International Immunopharmacology 109, 108838, 2022 | 7 | 2022 |
| Molecular docking of glyceroneogenesis pathway intermediates with peroxisome proliferator-activated receptor-alpha (PPAR-α) PA Subramani, K Panati, VR Narala Bioinformation 9 (12), 629, 2013 | 6 | 2013 |
| An overview on COVID-19 pandemic: from discovery to treatment K Panati, VRA Tatireddygari, VR Narala Infectious Disorders-Drug TargetsDisorders) 21 (7), 31-36, 2021 | 5 | 2021 |
